Good afternoon. Welcome to the Wolfe Healthcare Conference. My name is Mike Polark, medical device analyst here at Wolfe Research. Pleased in this session to be joined by Kestra Medical CEO Brian Webster, CFO Vaseem Mahboob. Brian and Vaseem, welcome. Thanks for being here.
Thanks, Mike.
Brian, I'll pass it to you to set the stage, and then we can jump into some Q&A. Maybe reflect on the last 18 Kestra's been public for about 18 months, call it a year and a half, almost two years. Just reflect on those couple years of the journey. Kestra's obviously been a much longer journey, but you're in growth mode, you're in execution mode. What stands out? What are you most proud of, and what excites you about the road ahead?
Yeah. Well, I appreciate the question, and Mike, thanks for having us here today. I think it's been quite a journey over the last 18 months. We went from sort of the shock treatment of trying to take a private company public and all the things that have to happen to do that effectively, all the process development, people development, all those things. We're kind of on, I think, mostly on the other side of that now, so those are becoming more a part of our normal cadence and our normal day. I think there's a couple things that we're really excited about. One, you've seen the steady execution coming from the company, and I think we really like to have a high say-do ratio.
When we say we're going to do something, we like to really be good at following through and doing that. I think so far we've been doing that, and that's because we've got just an amazing team. We're excited about the market. The market is growing. I'm sure we'll talk about that, but the more we get into the category and we understand the different patient needs and clinical needs, the more problems that we think we can solve. Ultimately, when you're a company that has a really strong engineering and clinical capability, that's what you're looking for. You're looking for problems to solve. I think we, across the company, are just really excited about solving more issues in the future and adding to our platforms and continuing to just drive what's a really exciting growth engine into the future.
Good setting of the stage. I will ask about the WCD market. I think we see Kestra's numbers, the growth rates are high. It's very clear you're taking share, but the incumbent here has a very large business, and they've talked more constructively about their WCD performance. I view this glass half full. It's good to see that. It validates the market opportunity, which is described as very large despite the incumbent having product in the market for two decades. I think it's very healthy. My question to you is, why? What are the one, two, or three things that you think are creating space for you to have great success and also helping, and that might also be helping their performance?
Well, I think first and foremost, you have to accept the fact that we came into the market and we solved a problem that was there. The reason that market, which I consider the kind of the classical WCD market to be the post-MI patient, the usually guy who's been revascularized. He's probably going to be a candidate for an implantable device in 45 or 90 days. The issue that we solved was wearability, was the false alarm issue, was all the gender specificity issue. All the things that were preventing that market from growing, we solved, so we're seeing that unfold. That's one reason why you're seeing the strong growth.
I think anytime you get a second company coming into a monopoly market, I think in med tech we've seen lots of cases like that where having somebody echoing the messaging around the need for that category always drives market growth, so that's pretty well established. Both companies, Kestra, we published about a year ago, we published our ACE-PAS, which is our FDA post-approval study data, 21,000 patients. Among the things that that study demonstrated was that the risk level for these patients was higher than most of the clinicians really appreciated, and in particular with the heart failure patients. We've been out there really beating the drums about that issue, and consequently, we're seeing more prescribers who are prescribing that maybe weren't prescribing to the broader range of their patients than they have before.
ZOLL also published a large study, a German registry study, that essentially showed the same thing. They are out selling the same message. When you have two companies with 40,000 patients worth of data echoing the same messaging around that category, that is what leads to market growth. On top of all those things, we are doing some really exciting stuff when it comes to medical education. We have had some really highly successful APP education programs recently in different locations around the country. I think it is a combination of all those things. By our math, with the ZOLL recent earnings release and our own, we see the market the last 12 months, it has grown at 14%. That is pretty healthy for a billion-dollar-plus category. We are pretty excited about that.
Do you have hard evidence to suggest heart failure is growing faster than post-MI, or do you believe both slices of hamburger?
It is definitely growing faster than post-MI. The population itself of patients who are experiencing heart failure is definitely growing faster, but we see in our own data that that patient population is growing faster than the post-MI patients. The nice thing for us, of course, in our model, in the rental model, is those heart failure patients are also longer wear patients, and longer wear has better economics attached to that. We are helping to solve a problem for that patient population, but that also is attractive economically.
On the prescriber comment, so existing prescribers prescribing more broadly, what about in the last year as market growth has perked up? What can you discern about new prescribers engaging with this product? Is it mostly the same store growth, or are there new stores, new prescribers that is meaningful?
I think our view is it's probably 75% of it's same store growth, and a quarter of it is new prescribers. There's definitely new prescribers that are seeing this. Especially what we're seeing is in some of our fellows programs where we're trying to really do some education with fellows, they really are attracted to newer technologies, updated modern technologies. They look at our kind of a device, and they look at it and say, "Hey, there's more utility to this than just a standard shock box," like they've been used to with a competitive device. They're looking at it as another tool that they can use to help manage these patients. That's been one of the drivers in some of those prescriber populations.
I'll ask on the guidelines. Heart failure in the U.S. still doesn't have guideline support, but between SCD-PROTECT and ACE-PAS, there's a substantial amount of new data, and I believe mostly that data is focused on this heart failure patient population. If I have it correct, the guidelines for WCD were last adjusted in 2017, 10 years ago.
What needs to happen next for some credit in the guidelines? Is there an identifiable pathway review timeline? Is this enough data, you think, to sway the guidelines, these two large studies, or is something more needed?
First, I think we all know that the guidelines process is not a well-defined start and stop process. Essentially, there has to be enough data that would cause that subcommittee that's looking, in this case, at the arrhythmia guidelines, for them to reconvene, reassess all that data, and then make decisions about whether to adjust the guidelines from today, what is mostly a 2b indication up to a 2a indication. We don't believe that a randomized trial is in order here, and none of our clinical advisors would support that because there's not an IRB that would approve it for ethical reasons, because the standard is out there with the WCD protection.
Getting randomized to nothing.
Yeah.
Yeah.
Yeah. Yeah. If you tried to redo the VEST trial, which was ZOLL's randomized trial, which was randomized to a WCD on one hand or nothing on the other, nobody's going to do the nothing on the other. There would be no benefit in doing a head-to-head at this point, because it would take so many patients to prove that, given the cardiac arrest rate. I think we believe that we can add more outcomes data to our dataset from the ACE-PAS data by going and getting the outcome data for that patient population. We think that's the missing link. All the other data that needs to be there is probably there.
In fact, recently, there was a HRS expert committee that convened and published a paper where they indicated strong, really a strong recommendation for the use of WCDs in some of these patient populations, including the ischemic cardiomyopathy patients, the heart failure patients. That's good that that happened sort of independently, and that just layers on top. I think when we continue to add some additional information, then I think it's pretty reasonable that that group will reconvene, and what they will assess is a lot more data than when they assessed in 2017.
The data you could add on top, ACE-PAS was a post-market study. It's completed, but you still have an open registry that's collecting, or what is the How are you generating the data that you think-
We have the ability to go back to the original patient population from ACE-PAS, so the 21,000 that we published, and get the patient outcomes from those that were delivered therapy and who wore the device. That is a missing piece of the puzzle right now that we believe if we can add that to the puzzle, then we believe that will be, and obviously, if it's positive, then that will be enough to get them to the table.
Is that survival data?
Yeah.
Post-shock and.
Yeah.
Okay.
Yeah.
It sounds like close, perhaps not imminent, but I'll remember from another executive, you can grow old and have a completed career by the time the guidelines update. Not critical.
Yeah
but would be corroborative and supportive at some point.
Yeah, I think there's nothing about the guidelines that is driving our long-range model. We're not building anything into it. We believe this business is going to grow at the top decile of med tech without guidelines changes. If guidelines change, then I think you're talking about a different animal, and the growth would really, really get accelerated. We're not counting on it, but we're certainly working towards it. Yeah.
All right, good. Let's shift gears. Very much in execution mode, hiring lots of folks, territory creation. Been public for a while, so the awareness is out there, and the performance has been good. Just talk about the hiring environment for what you're looking for today versus, say, last year or the year before that, maybe the quality of candidates and your process. Has it changed? Are you looking for someone different today than you were looking for two years ago? If so, how?
I think as we've gotten more experience in the category, I think we've refined what we're looking for, but I don't think it's dramatically changed. We've built our own internal recruiting engine, so we do it internally. We have a bunch of really highly capable, highly motivated people that are doing that. I think the market has changed a little bit, probably just in the last 12 months, given some of the things going on with some of the big cap cardio companies. There's more of those people that are in the funnel now that we hadn't seen as full. I would say we probably have more folks coming from those companies today than we did 12 months ago. There's a little bit maybe more concentration around it.
The actual recruiting process, we have a really well-defined process that we execute and do a pretty good job of that. Ultimately, recruiting comes down to what territory you're recruiting for, and they're not all created equal. Some of them, you can get a lot of talent in a given territory. Others, it takes a while to find just the right person for that particular scenario. We feel pretty good about our ability to recruit, and we've made a lot of investment in the post-recruitment process, which is, okay, now we've got them on board, and now let's get them trained up. We've essentially doubled the amount of time that we take for the training process after we hire them, and we're seeing some really good results from that investment.
The training itself is longer, but for a faster productivity ramp-
That's right.
Is that the return?
Yeah.
What about what has been added to the training that was not in there before?
I think a lot more scenario planning, territory planning. We have made some really good investments in the data platforms that allow us to do the territory planning, like where are the opportunities in that given territory and how we think about that. In the original days, we had this sort of stale Medicare data that we used for prescriber targeting and things like that. Now we have a lot richer data, so that is part of the sales academy training. We also do a lot more scenario role-playing and just getting them ready to deal with the issues that they are going to deal with in the field. I think it is a combination really of all those things.
Another example would be we have added in how to get in the EMR in your accounts, and that was sort of a one-off thing in the early days, but now there is a process that people know exactly how to go about that. There is a number of things like that that we have just really upped our game, and we have seen the benefit of that. We are seeing people come up that curve more rapidly, and that is what the whole investment was all about.
What about your vision for covering the country? Just how much of it do you think you cover well today? How much of it do you still have to cover? Anything evolving as you have balanced breadth versus depth of territories based on the last couple years of experience?
Yeah, I think right now we're probably somewhere around 70% coverage. It's a little bit of a tricky metric when you think about it, because you can say, "Okay, I have a rep in this, pick a city, in Charlotte, and so I'm covering Charlotte." The competitor may have four reps there, so it's not truly head-to-head in terms of being able to cover it. But I think for us, it's making sure that we are putting reps in the territories where we have good insurance coverage, where we have good indication that there's heavy prescriber concentration. Then, I think we're more likely to go deep in accounts and in regions than we are to go wide. There will be time later to go wider, but I think we're going deeper. We're making sure that in the really high-producing regions, that we've got the resources that we need.
What we're seeing is when we fully resource, we're seeing the business is really accelerating.
It might have been a few calls ago now, there was a mention of sole source, just Kestra. The alternative is no longer. How prevalent is that model? I mean, obviously, it's a good dynamic. It's constructive to hear you winning a situation like that. Was that an outlier, or do you think there's room for hospitals just using a single vendor for WCD as the future rule? If so, what are the things you can do to persuade customers to make that choice?
I think it's probably not going to be the majority of situations, and mostly where you'll see opportunities for that will be in the IDN-style organizations where they've got full womb-to-tomb control over it. In the general, like a university hospital or something like that, we're not really contracting with the hospital itself. We're selling to one doc at a time. So, you don't really see that scenario as much because it's also harder to be able to show the full benefit in terms of economic benefit of quicker discharge from the hospital, fewer readmittance from the hospital.
And some of these IDNs are really interested in that kind of data. They look at our monitoring platform and they say, "Hey, we can use that data to help us with readmittance and things like that." I think we'll continue to see some progress in those kind of institutions, but I don't see it as being the full, "Hey, we're going to just kind of run across the country doing that.
Let's shift gears. I want to hit on kind of supply side product and capacity, and then I want to hit on revenue cycle too. Maybe to start on product. You're growing at a very high rate. You're hiring lots of folks. The model is for high rates of growth ahead. There's always that sweet spot of driving fast but not losing control. You have a refurbishment kind of element to your solution, and then there's a disposable-
element. You feel good that you can supply all the growth that you're working for? Talk to me about the supply chain manufacturing side of the equation and how you stay ahead of that curve.
Yeah. I think our ability, especially in the early years, we're a year and a half into this public journey. I think the ability to ramp the business rapidly in this first couple of years will be somewhat governed by the ability to ramp supply chain, because it is so rapid. But we're making investments in all of our top tier 1, tier 2 suppliers to add additional capacity, as we've always planned, but we're making those investments now to make sure that capacity is always ahead of the demand. In this first couple of years, I think we are somewhat governed by supply, but that's in a controlled way. We have a good supply chain that has the ability to ramp. We're actively working that.
The big question is always, well, how much capacity do you need and how fast do you need to ramp that, and how do you balance that with your investments in inventories and CapEx and things like that? This is part of the daily navigation that we're doing. But I think each of the suppliers that we have, by design, has the ability to ramp up quite dramatically so that we will, as we look at the next three, five years, we will have the ability to ramp the business as we add all these salespeople and continue to add innovation and all that kind of stuff.
Revenue cycle. You are a provider. You bill and collect directly, and I forget the number, but there's a lot of payers in the U.S., and it takes time to get to know them and how they'll pay and how they'll ask you questions and so forth. So, maybe for Vaseem, portion of lives in network today, where is it? Where were you this time last year? I've always A portion of the book is on cash accounting, and this, I think, if I'm framing it correctly, is a function of you're getting to know these payers and your ability to collect from all that sort of stuff. Eventually, the experience will be sufficient such that you move to accrual, and it may turn out in that moment, you can accrue at a higher rate. Where are we in that process?
What's just the in-network coverage today, and how close are we to the entire book being on kind of an accrual method of accounting?
Yeah, so to your point, we've made a lot of progress in the last year and a half. If you remember when we went public, we had 67% of our patients were in-network. We're in the low 80s now, so really good progress. All of the big headline payers in the U.S., nationals, we're all in-network with them, have been in-network for a long time. And are now on that process or journey to collect all of that historical collection data, take it to our auditor, and get them converted one at a time into accrual accounting. So we know the playbook, we know the process. It's just a matter of time. It's just going to happen steadily in the next 12 to 18 months. On the number of payers, there's about 3,200-plus payers in the U.S.
Even the incumbent, we know in that SCD-PROTECT data that they published out of Germany, they actually mentioned their 98% kind of covered lives in terms of the national number. But the actual mix of patients that they see is in the low 90s. It is very typical in most industries to have that 5-6 point delta. It happens for good reason. People are moving between employers, so they are actually changing coverages. There are people that are falling in and out of different plans and things like that. So really, for us, the gap to close, Mike, is to go from that low 80s to the low 90s, and we are on our way to do that.
Let us shift gears again. Pipeline. There was a mention last call about R&D expense one-timer, kind of an unusual thing. It was like in the numbers, but you did not say anything else about it. A project that was to soon be submitted to FDA. Are you at a point where you can say more about what that is and why it is important?
Yeah. The reason we brought that up at the last earnings call was because it was a spike in our R&D expense. As we said back then, we had an opportunity on a project that we had been working on for about three years, an internal development project, to accelerate it and get it over the finish line. So we applied some financial resource to be able to do that. So that is why we brought it up. We are not quite ready to talk about it. I expect we will be ready before the end of the calendar year to talk about it. So it is imminent, and we are just waiting to the point that we have gotten past the final milestone in terms of submission to the regulatory agencies before we are ready to talk about it.
It is a meaningful innovation in our space and a meaningful clinical benefit that will be added to the platform. It also will give us a real exciting additional platform as we go through time and we continue to innovate into that capability. So, it is coming. We will talk about it soon.
I look forward to it. I know you're not going to say what it is here. We'll move on, but I look forward to learning more.
Right.
Something you can talk about is Biobeat.
Kind of another pipeline element. Ambulatory blood pressure monitoring. What's the current vision for that, integrating it into ASSURE or something standalone? Just talk about the product development roadmap there, and then maybe in parallel, if you do something interesting there, how do you get paid for it?
Well, it's another technology that we're very excited about. One of the things that we did when we developed the platform, the ASSURE platform, was we wanted to make sure that the platform itself was able to bring in other technologies, other appliances, if you will, and that we had architected it in such a way that we could do that. Because we knew that our longer-term vision was that this was much more than a shock box. That's what the competitive device has always been. We view this as a high-performance monitor defibrillator that people are going to go home and they're going to wear, and it's going to give them, patients and clinicians, a lot of information about that patient. The first step, the next step is the non-invasive blood pressure. Biobeat is unique in that they are the only FDA-approved wireless patch-based non-invasive blood pressure monitor.
70% of the patients in our ACE-PAS data were hypertensive. I can tell you that as we talk to physicians about this technology, they're also very interested in the hypotensive patients, the really slow, really low heart rate patients. This is going to give us the ability to help them with both kinds of patients. Our goal is going to be to integrate it into the platform. We don't see it as We're not interested in being a third-party distributor of their product where we're just throwing their patch-based system into our bag and saying, "Hey, stick that on and off you go." We're going to integrate it into our platform, so that when a patient puts on the platform, and if the physician has selected that as a diagnostic capability that they want, then they will get that, and the patient will automatically have that ability.
That'll be integrated not only in the hardware, but also into the software, so that when the physician pulls up the Kestra CareStation portal, they'll get not only all the ASSURE data, but they'll also get the non-invasive blood pressure data all integrated in. That's what the R&D project is all about, that we're making good progress on. The two teams are working well together and just tackling normal kind of R&D project issues. We're excited about where that goes. It does have its own existing reimbursement code. We're doing a bunch of work trying to figure out how that code will be applied in the way we're going to implement it, because we're going to implement this more as a long-term wear, as opposed to the current Biobeat reimbursement is for five to seven days.
We've got to navigate what that would mean in our situation, but there is an existing code, and we'll be working to make sure that we get some economics coming from that.
It sounds like a step on the journey of multi-vitals.
Yeah.
I hear that in this world, yeah.
100%.
Okay. And you already have ECG and
Yeah
pressure, and then
Well, we
Is there room on the WCD for more?
Absolutely. When you get a patient, and that patient is going to wear the device for over three months, and increasingly with these heart failure patients, could be four or five months, we've gone to all the work to get them to wear this system. Our view is, if we can figure out how to derive additional clinical utility, then that just makes our product more valuable, and that makes us more likely to be the choice.
Right at the start of a project like this Biobeat project, there is the differentiation capability where a prescriber is going to look at our prescription sheet and say, "Well, gee, they have a box here for non-invasive blood pressure monitoring, and I see that the competitor doesn't, and I would really like that, and so I'm going to pick these guys." That's at the start. That's before we even talk about any reimbursement and things like that that we may get. It's the start of a journey towards having the ability to measure a bunch of different diagnostic qualities of these patients and provide that to these docs so that they can manage them, especially as they're titrating them off of the drug treatments for heart failure.
That's a good way to wrap, vision for the future. Brian and Vaseem, thank you for being here.
Okay.
Thanks for having us.
Thanks, Mike.
Great time. Yep.
Appreciate it.